Image Sourced ShutterStock
Market Herald logo


Be the first with the news that moves the market
  • Medicinal cannabis producers Althea will supply UK pilot with company products. The study is seeking 20,000 patients
  • The pilot, run by Drug Science, hopes to inspire change in regulations surrounding medical cannabis
  • Althea’s share price is up nearly 6.5 per cent this morning, currently sitting at $1.07 per share.

Althea will supply the first UK medical cannabis pilot. The company is looking to sign up 20,000 patients by the end of 2021.

Althea was selected to supply its products to the pilot from a select number of companies. These will be supplied on commercial terms.

Independent UK advisory committee, Drug Science, are conducting the pilot.

The study will target patients suffering from chronic pain, PTSD (focus of veterans), anxiety, multiple sclerosis and tourettes.

It is noted a focus will be placed on patients who haven’t had success with alternative treatments.

Chief Scientific Officer at Drug Science, Professor David Nutt said the pilot “will allow patients to get vital therapy without breaking the law”.

The pilot, named Project TWENTY21, intends to comprise a set of data which will be used to support making medical cannabis readily available.

CEO of Althea Dr Robert Pawinski said “we believe the pilot program will yield valuable data that can then be used to further bolster the case for wider medicinal cannabis used and inform public health and stakeholder decisions”.

Results from the study will be submitted to UK health authorities, which both companies hope will lead to a change in regulation surrounding prescribing medicinal cannabis.

The pilot will “provide a solid clinical database from which experience of and confidence in medical cannabis prescribing will develop. Providing a foundation for other medical prescribers to build on,” Professor Nutt said.

Project TWENTY21 officially commences on 18 July 2019.

Althea’s share price is up nearly 6.5 per cent this morning, currently sitting at $1.07 per share.

AGH by the numbers
More From The Market Herald
Heramed (ASX:HMD) - CEO and Co Founder, David Groberman

" HeraMED (ASX:HMD) raises $2.39m via convertible note placement

HeraMED (HMD) has raised roughly $2.39 million through a convertible note placement.
NeuroScientific Biopharmaceuticals (ASX:NSB) - MD and CEO, Matthew Liddelow

" NeuroScientific Biopharmaceuticals (ASX:NSB) completes safety pharmacology studies

NeuroScientific Biopharmaceuticals (NSB) has seen no adverse events during its non-clinical studies of EmtinB.
PharmAust (ASX:PAA) - Chief Scientific Officer, Dr Richard Mollard

" PharmAust (ASX:PAA) identifies optimal MPL dose for canine cancer

Clinical-stage biotech company PharmAust (PAA) has identified the optimum monepantel (MPL) drug plasma range for dogs with B-cell lymphoma.
Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke

" Alcidion Group (ASX:ALC) extends contract with Sydney Local Health District

Alcidion Group (ALC) has expanded the use of its remote patient monitoring platform, Miya Precision, with the Sydney Local Health District (LHD).